2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

hypopharyngeal cancer cells

" in MedChemExpress (MCE) Product Catalog:

4

Inhibitors & Agonists

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0757
    8-​O-​Acetylharpagide
    1 Publications Verification

    		 Akt Bcl-2 Family Apoptosis Adrenergic Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    8-O-Acetylharpagide is an orally active iridoid glycoside compound. 8-O-Acetylharpagide exhibits anti-aging activity at low doses and anticancer activity at high doses. 8-O-Acetylharpagide induces late-stage apoptosis and necrosis-like death in cancer cells, and downregulates anti-apoptotic proteins such as Akt, p-Akt and Bcl-2. 8-O-Acetylharpagide is mainly metabolized in rats via demethylation, hydrolysis and glucuronidation, and its active metabolites downregulate the AKT/NF-κB/MMP9 signaling axis. 8-O-Acetylharpagide exerts vasoconstrictive effects by activating vascular α-adrenoceptor .
    8-​O-​Acetylharpagide
  • HY-168878
    EP652

    		METTL3 Cancer
    EP652 is a METTL3 inhibitor and antitumor agent with IC50 values of 2 nM, <10 nM, and 37 nM in SPA, intracellular, and ATPlite assays, respectively. EP652 exhibits high selectivity against 40 other methyltransferases and FTO, and possesses favorable pharmacokinetic parameters. EP652 reduces intracellular N 6-methyladenosine (m 6A) levels in mRNA. EP652 inhibits tumor growth and progression of both hematologic malignancies and solid tumors. EP652 can be used for the research of acute myeloid leukemia, ovarian cancer, non-small cell lung cancer, and hypopharyngeal squamous cell carcinoma .
    EP652
  • HY-181567
    METTL3-IN-13

    		METTL3 Cancer
    METTL3-IN-13 is a METTL3 inhibitor. METTL3-IN-13 is applicable to the research of multiple cancers such as hypopharyngeal squamous cell carcinoma and non-small cell lung cancer .
    METTL3-IN-13
  • HY-183513
    L-Ala-BPA

    		FAP Cancer
    L-Ala-BPA is a boron delivery agent. L-Ala-BPA is transported into tumor cells via PEPT1/2 and LAT-1 (SLC7A5) pathways and is rapidly cleaved systemically by endogenous proteases including FAP to yield L-BPA (HY-W087830). L-Ala-BPA shows antitumor activity and can be used for the research of Boron Neutron Capture Therapy (BNCT) .
    L-Ala-BPA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: